Javier Moncayo-Arlandi

Javier Moncayo-Arlandi

Auto-generated profile, based on publicly available information

Javier Moncayo-Arlandi

Cardiovascular Genetics Centre, Girona Institute of Biomedical Research (IDIBGI), Carrer del Dr. Castany, s/n, 17190 Salt, Girona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2015 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
NGNahuel Aquiles García
Nahuel Aquiles García
JMJavier Moncayo-Arlandi
Javier Moncayo-Arlandi
Pilar SepúlvedaPilar Sepúlveda
Pilar Sepúlveda
Antonio Díez-juanAntonio Díez-juan
Antonio Díez-juan
Cardiomyocytes (CMs) and endothelial cells (ECs) have an intimate anatomical relationship, which is essential for maintaining the metabolic requirements of the heart. Little is known about the mechanisms that regulate nutrient flow from ECs to associated CMs, especially in situations of acute stress when local active processes are required to regulate endothelial transport. We examined whether CM-derived exosomes can modulate glucose transport and metabolism in ECs. In conditions of glucose deprivation, CMs increase the synthesis and secretion of exosomes. These exosomes are loaded with functional glucose transporters and glycolytic enzymes, which are internalized by ECs, leading to increased glucose uptake, glycolytic activity, and pyruvate production in recipient cells. These findings establish CM-derived exosomes as key components of the cardio-endothelial communication system which, through intercellular protein complementation, would allow a rapid response from ECs to increase glucose transport and a putative uptake of metabolic fuels from blood to CMs. This CM-EC protein complementation process might have implications for metabolic regulation in health and disease.

13 July 2017 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
JMJavier Moncayo-Arlandi
Javier Moncayo-Arlandi
RBRamon Brugada
Ramon Brugada

8 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RTROCIO TORO
ROCIO TORO
APAlexandra Pérez-Serra
Alexandra Pérez-Serra
Oscar CampuzanoOscar Campuzano
Oscar Campuzano
JMJavier Moncayo-Arlandi
Javier Moncayo-Arlandi
CACatarina Allegue
Catarina Allegue
RBRamon Brugada
Ramon Brugada
Dilated cardiomyopathy, a major cause of chronic heart failure and cardiac transplantation, is characterized by left ventricular or biventricular heart dilatation. In nearly 50% of cases the pathology is inherited, and more than 60 genes have been reported as disease-causing. However, in 30% of familial cases the mutation remains unidentified even after comprehensive genetic analysis. This study clinically and genetically assessed a large Spanish family affected by dilated cardiomyopathy to search for novel variations. Our study included a total of 100 family members. Clinical assessment was performed in alive, and genetic analysis was also performed in alive and 1 deceased relative. Genetic screening included resequencing of 55 genes associated with sudden cardiac death, and Sanger sequencing of main disease-associated genes. Genetic analysis identified a frame-shift variation in BAG3 (p.H243Tfr*64) in 32 patients. Genotype-phenotype correlation identified substantial heterogeneity in disease expression. Of 32 genetic carriers (one deceased), 21 relatives were clinically affected, and 10 were asymptomatic. Seventeen of the symptomatic genetic carriers exhibited proto-diastolic septal knock by echocardiographic assessment. We report p.H243Tfr*64_BAG3 as a novel pathogenic variation responsible for familial dilated cardiomyopathy. This variation correlates with a more severe phenotype of the disease, mainly in younger individuals. Genetic analysis in families, even asymptomatic individuals, enables early identification of individuals at risk and allows implementation of preventive measures.

12 December 2012 in SpringerPlus
Verified
Journal Article
Open access
PDF file
DLDavid Lara-Astiaso
David Lara-Astiaso
AIAlberto Izarra
Alberto Izarra
JEJuan Camilo Estrada
Juan Camilo Estrada
CACarmen Albo
Carmen Albo
IMIsabel Moscoso
Isabel Moscoso
Antonio Díez-juanAntonio Díez-juan
Antonio Díez-juan
Cardiac healing, which follows myocardial infarction, is a complex process guided by intricate interactions among different components. Some resident cell populations with a potential role in cardiac healing have already been described in cardiac tissues. These non-cardiomyocyte cell subsets, globally described as cardiac pluripotent/progenitor cells (CPCs), are able to differentiate into all three major cardiac cell lineages (endothelial, smooth muscle and cardiomyocyte cells) in experimental settings. Nevertheless, physiological cardiac healing results in a fibrous scar, which remains to be fully modelled experimentally. Since a role for complement anaphylatoxins (C3a and C5a) has been described in several regeneration/repair processes, we examined the effects that C3a and C5a exert on a defined population of CPCs. We found that C3a and C5a are able to enhance CPC migration and proliferation. In vitro studies showed that this effect is linked to activation of telomerase mRNA and partial preservation of telomere length, in an NFκB-dependent manner. In addition, anaphylatoxin signalling modulates the CPC phenotype, increasing myofibroblast differentiation and reducing endothelial and cardiac gene expression. These findings may denote that C3a and C5a are able to maintain/increase the cardiac stem cell pool within the heart, whilst simultaneously facilitating and modulating resident cell differentiation. We found that this modulation was directed towards scar forming cells, which increased fibroblast/myofibroblast generation and suggests that both these anaphylatoxins could play a relevant role in the damage-coupled activation of resident cells, and regulation of the cardiac healing process after injury.

12 July 2016 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
JMJavier Moncayo-Arlandi
Javier Moncayo-Arlandi
EGEduard Guasch
Eduard Guasch
MGMaria Sanz-De la Garza
Maria Sanz-De la Garza
MPMarta Casado Pinna
Marta Casado Pinna
NGNahuel Aquiles García
Nahuel Aquiles García
RBRamon Brugada
Ramon Brugada
Arrhythmogenic cardiomyopathy (ACM) is a disorder characterized by a progressive ventricular myocardial replacement by fat and fibrosis which lead to ventricular arrhythmias and sudden cardiac death. Mutations in the desmosomal gene Plakophilin-2 (PKP2) accounts for >40% of all known mutations, generally causing a truncated protein. In a PKP2 truncated mouse model, we hypothesize that content of transgene, endurance training and aging will be determinant in disease progression. In addition, we investigated the molecular defects associated with the phenotype in this model. We developed a transgenic mouse model containing a truncated PKP2 (PKP2-Ser329) and generated three transgenic lines expressing increasing transgene content. The pathophysiological features of ACM in this model were assessed. While we did not observe fibro-fatty replacement, ultrastructural defects were exhibited. Moreover, we observed transgene content-dependent development of structural (ventricle dilatation and dysfunction) and electrophysiological anomalies in mice (PR interval and QRS prolongation and arrhythmia induction). In concordance with pathological defects, we detected a content reduction and remodeling of the structural proteins Desmocollin-2, Plakoglobin, native Plakophilin-2, Desmin and β-Catenin as well as the electrical coupling proteins Connexin 43 and cardiac sodium channel (Nav1.5). Surprisingly, we observed structural but not electrophysiological abnormalities only in trained and old mice. We demonstrated that truncated PKP2 provokes ACM in absence of fibro-fatty replacement in the mouse. Transgene dose is essential to reveal the pathology, whereas aging and endurance training trigger limited phenotype. Molecular abnormalities underlay the structural and electrophysiological defects.

1 December 2014 in Atherosclerosis
Verified
Journal Article
Closed access
JMJavier Moncayo-Arlandi
Javier Moncayo-Arlandi
ALAlejandro López-García
Alejandro López-García
MFM. Carmen Fernández
M. Carmen Fernández
ABAna Carmen Durán Boyero
Ana Carmen Durán Boyero
BFBorja Fernández
Borja Fernández